Technology
Tech Titans Tumble
May 30, 2025
When it came time to guess the retail price of Apple’s Vision Pro headset on The Price Is Right, four contestants were way off — underestimating by more than $2,000 each. The crowd’s audible groans said it all when the actual cost was revealed. Meanwhile, on the markets, it was a bit of a topsy-turvy day: smaller stocks in the S&P 500 pushed indexes higher, while the usual big tech names took a step back. The S&P 500 rose 0.4%, the Nasdaq edged up 0.1%, and the Russell 2000 led gains with a 0.5% bump. Defensive sectors like utilities and staples led the pack, while consumer discretionary lagged behind.
Here’s a quick brain teaser for you: What’s the most common name for popes? Test your knowledge in our Snacks Seven Quiz! And if you have some big questions of your own, why not share them in our survey? We want to keep bringing you stories that hit the spot.
Walmart’s recent earnings call carried a cautionary note: CFO John David Rainey flagged upcoming price increases, expected to start hitting shelves by late May and definitely by June. Although Walmart’s shares popped early in the day, the company ultimately closed lower, reflecting concerns about how consumers will react to rising costs. The retailer is also scaling back some orders, closely watching customer sensitivity to price changes.
Walmart’s efforts to manage costs include pressuring Chinese suppliers to reduce prices by up to 10% amid ongoing tariff tensions — a tricky dance, given that roughly 60% of its shipments came from China last year. Experts say Walmart’s massive scale gives it pricing leverage, allowing it to keep prices lower than competitors even when hikes are necessary. Still, rising prices are rising prices, no matter how you slice it.
Presented by Turn Therapeutics
When faced with a deadly infection boasting a 70% fatality rate and no existing cure, Bradley Burnam did what most wouldn’t dare—he created the solution himself. Enter Hexagen: a groundbreaking formula that Burnam personally shepherded through the FDA clearance process for just $24,000. But he didn’t stop there. Building on this success, Burnam expanded the technology, secured two additional FDA clearances, and founded a company that’s rewriting the rules on self-made medical innovation: Turn Therapeutics.
Hexagen isn’t just breaking barriers; it’s healing them. Cleared for acute wound care and atopic dermatitis, this powerhouse formula is now on the brink of a bigger leap. Turn, the company behind Hexagen, is paving the way to expand its applications, proving there’s much more to its potential than meets the eye.
Turn just locked in a game-changing commitment—up to $75M in investment from GEM Global Yield Fund. This private equity boost is tied to the company’s plans to go public, setting the stage for Turn to make bold moves in the market spotlight..2
Turn is rolling out institutional, accredited, and unaccredited investors to participate in their current crowdfunding campaign — but only until January 2025.3
Cisco shattered expectations with stellar earnings and raised guidance, propelled by AI infrastructure demand exceeding $1 billion a year ahead of schedule. CEO Chuck Robbins highlighted enterprise customers’ relentless investment in AI, noting, “They’re committed to the transition until they absolutely have to stop.”
This level of spending underscores how much the current tech and market boom shapes corporate behavior — companies are chasing the next breakthrough, and investors reward those perceived as fully engaged in the AI wave. The takeaway? In a mania-driven market, the biggest fear isn’t failure; it’s missing out.
After a rough start to the year, retail investors betting on buy-the-dip strategies have begun to see green, according to JPMorgan analysts. April’s surge in stocks like Tesla, Palantir, and Nvidia helped them narrow losses compared to the broader market. Curious what retail traders have been snapping up lately? Check out the highlights.
Presented by Atombeam
Big tech, small data… Why are industry leaders like NVIDIA, Intel and Ericsson partnering with Atombeam?1 It’s the company reimagining machine communication — and potentially the future of big tech. That’s thanks to Neurpac, Atombeam’s patented software technology that can reduce the size of low-entropy data by an average of 75%.
Lightning fast… Neurpac enables 2-4x more data to be sent faster and more securely over existing networks—no hardware upgrades — just smart, AI-powered software.
To the moon and back… The U.S Space Force and U.S. Air Force have already been on Atombeam’s customer books — and the company’s potential market is still gaining ground. Atombeam is in discussions with multiple companies, ranging from a major packaging brand to an EV enterprise.
$16M has already been invested into the company. You can invest before the round closes in 29 days.2
1 The partnership relationship varies between companies and can include the following: inclusion on a preferred vendor list, invitations to participate in certain forums; listed on the other company's website, and introduction and networking opportunities.
Advertiser's disclosures:
¹ The Company's Formula (Gx-03/Hexagen/Atopx) Has Received 510k Marketing Approval As A Medical Device Indicated For The Management Of Symptoms Related To Atopic Dermatitis/Eczema. The Formula Has Not Received Approval As A Drug For The Treatment Of Eczema Or Onychomycosis.
² A plan to IPO is no guarantee that an actual IPO will occur.
³ Please read the offering circular and related risks at StartEngine’s Turn Therapeutics webpage. This is a paid advertisement for Turn Therapeutics Regulation CF Offering. This Reg CF offering is made available through StartEngine Primary, LLC, member FINRA/SIPC.
Investing in private company securities is not suitable for all investors because it is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities.
